Background: Hypertension is more prevalent among HIV-infected individuals than in the general population and contributes to increased cardiovascular risk. The angiotensin II receptor blocker telmisartan is also a partial peroxisome proliferator activated receptor-γ agonist with documented effects on glucose and lipid homeostasis. The aim of this study was to evaluate the antihypertensive and metabolic effects of telmisartan in hypertensive HIVpositive patients. Methods: A total of 18 HIV-positive men treated with antiretroviral therapy and recently diagnosed with hypertension were administered 80 mg telmisartan daily. Systolic blood pressure (SBP) and diastolic blood pressure (DBP), viroimmunological and metabolic parameters, insulin resistance, C-reactive protein, microalbuminuria, cystatin C and plasma levels of interleukin-18 and endothelin-1 were measured at baseline (T0), 1 month (T1), 3 months (T3) and 6 months (T6).
Results: Treatment with telmisartan not only decreased SBP and DBP levels, but also improved insulin resistance and microalbuminuria by T1. Levels of triglycerides significantly decreased and high-density lipoprotein cholesterol increased at T1, whereas total and low-density lipoprotein cholesterol levels were statistically reduced at T3 and T6. Cystatin C and endothelin-1 showed a significant reduction at T1, whereas interleukin-18 decreased at both T3 and T6. Conclusions: Telmisartan was effective in reducing blood pressure and improving lipid metabolism and renal function. Reduction of endothelin-1 might be related to an endothelial protective effect. On the basis of these findings, and because of properties unrelated to blood pressure lowering, telmisartan might be the first choice antihypertensive drug for the treatment of HIV-positive patients.
Hypertension is the major cardiovascular risk factor worldwide, influencing cardiovascular morbidity and mortality in the general population [1] . The prevalence of hypertension in HIV-infected patients varies greatly among populations and races, ranging from 8 to 34% [2] [3] [4] . Some studies have shown that hypertension is more prevalent among HIV-positive than HIV-negative patients [3] , despite conflicting results in large multicentre studies on the putative effects of combination antiretroviral therapy (cART) on the development of hypertension [5] [6] [7] . Large epidemiological studies have found that HIV-infected patients are likely to be at higher risk for premature cardiovascular diseases (CVD) compared with the general population [8] . Therefore, treatment of hypertension is of pivotal importance in HIVpositive individuals to prevent end-organ damage and ultimately reduce CVD and mortality. Although several antihypertensive drugs are available, the choice must be made carefully in HIV-positive patients because of possible interactions with cART and the coexistence of metabolic abnormalities.
In the past few years attention has focused on antihypertensive drugs that block the renin-angiotensin system, including angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin type 1 (AT1) receptor blockers (ARBs; sartans) [9] . Such drugs have become a cornerstone for the treatment of hypertension and their use has reduced cardiovascular morbidity and mortality in the general population [10] Introduction telmisartan has the strongest peroxisome proliferator activated receptor-γ (PPAR-γ)-activating properties at plasma concentrations used in the treatment of hypertension; this ability is unrelated to AT1 receptor antagonism [11] [12] [13] [14] .
As PPAR-γ agonists not only improve insulin resistance by ameliorating carbohydrate and lipid metabolism, but also protect against oxidative stress induced injury in various organs [15] , telmisartan is considered a 'cardiometabolic sartan', targeting both diabetes and CVD in hypertensive patients [16, 17] . Besides efficiently controlling blood pressure, telmisartan has favourable effects on insulin sensitivity, lipid profile and inflammatory parameters [18] [19] [20] [21] and apparently prevents progression of end-organ damage in hypertensive patients with or without diabetes [22] .
Data on the effects of telmisartan in HIV-positive patients are lacking. The aim of this study was to evaluate the effects of telmisartan in HIV-infected male patients treated with cART and a recent diagnosis of hypertension.
Methods
This was an observational study on consecutive outpatients attending the Clinic of Infectious Diseases at the SS Annunziata Hospital, 'G d'Annunzio' University of Chieti-Pescara, Italy, from January to December 2008.
Study population
The study population included 18 Caucasian male HIV-positive patients who had been on cART without therapeutic changes for >12 months; all patients included had an HIV RNA titre <40 copies/ml and a CD4 + T-cell count constantly >300 cells/ml in the 6 months before the start of the study. Female gender was a baseline exclusion criteria, as hormonal status and possible pregnancy could potentially affect the use and effects of antihypertensive drugs. All patients had a recent diagnosis of Grade 1-2 hypertension according to the European Society of Hypertension criteria [23] .
A number of patients were excluded from participation: patients using ketoconazole, steroids, growth hormones, testosterone or any anabolic agent in the previous 6 months; patients engaged in drug abuse or with an acute infection in the previous 3 months; patients with kidney disease and glomerular filtration rate assessed by the simplified Modification of Diet Renal Disease logarithmic model (MDRD-GFR) ≤50 ml/min/1.73 m²; and patients treated with other antihypertensive agents before the beginning of the study.
All patients were treated with telmisartan at a dose of 80 mg administered orally once daily. Participants were asked to adhere to their usual diet and lifestyle during the study.
Height and weight were measured with the patients wearing indoor clothes without shoes. The body mass index (BMI) was calculated as weight in kilograms divided by the square of their height in metres.
Measurement of blood pressure and heart rate were made in duplicate at each clinic visit, 24 h after the intake of the study medication. Duplicate measurements were taken separated by a ≥5 min interval, after the patients had rested in sitting position for ≥5 min. Ambulatory blood pressure was approximated to the nearest 2 mmHg in the same arm at each visit using a mercury sphygmomanometer (Erka Medical, Bad-Tölz, Germany) with an appropriately sized cuff. Heart rate was measured by pulse palpation for 30 s immediately after the blood pressure measurement.
The Framingham Risk Score was used to estimate the probability of a first incident coronary event in the next 10 years [24, 25] . This score was selected because of its reproducibility, its easy clinical use and its widespread use in several studies on HIV-positive patients.
The study was conducted in accordance with the guidelines proposed in the Declaration of Helsinki. All patients gave informed consent to the study and the protocol was approved by the Ethics Committee of the 'G d'Annunzio' University School of Medicine (Chieti, Italy).
Biochemical analyses
A fasting venous blood sample was collected from all participants at the time of the first clinic examination (T0), at 1 month (T1), 3 months (T3) and 6 months (T6). Blood was taken from an antecubital vein to determine plasma levels of glucose, triglycerides, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, C-reactive protein, erythrocyte sedimentation rate (ESR), insulin, aspartate aminotransferase, alanine aminotransferase, γ-glutamyltranspeptidase, creatinine, urea nitrogen and uric acid. Routine laboratory tests were performed at the Division of Clinical Pathology in the same hospital.
Insulin resistance was determined using the homeostasis model assessment index (HOMA-IR) with the formula: (fasting insulin level in µU/ml × glucose level in mmol/l)/22.5.
The glomerular filtration rate was assessed using the simplified MDRD logarithmic model, which takes into account levels of plasma creatinine, age, gender and race [26] .
Measurements of serum cystatin C were performed on fresh fasting blood samples by a BN II nephelometric system (Siemens Healthcare Diagnostics, Inc., Deerfield, IL, USA) employing a particle-enhanced immunonephelometric assay.
Microalbuminuria was measured on singleday urine samples using a particle-enhanced immunonephelometric assay (BN II System; Siemens Healthcare Diagnostics, Inc.).
Plasma levels of interleukin-18 (IL-18) and endothelin-1 were determined by enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN, USA).
Virological and immunological markers

CD4
+ and CD8 + T-cell counts were obtained by flow cytometry of lymphocyte subpopulations. Plasma viral load (HIV RNA) was determined using the Amplicor method (Roche Molecular Diagnostics, Milan, Italy), which has a detection limit of >40 HIV RNA copies/ ml of plasma.
Statistical analysis
Data are reported as mean ±standard deviation for continuous variables and as frequency and percentage for categorical ones.
Differences between blood pressure mean values at T0, T1, T3 and T6 were tested by mixed-models analysis of covariance (Proc Mixed). The advantage of this approach is that it increases the precision of the estimate by using all available information and, at the same time, allows the handling of missing data. The analysis was adjusted for age and sex. The P-values reported for comparisons between different time points of the study were Bonferroni-adjusted. Moreover, the P-value for trend was also calculated to evaluate the graded (and thus potentially causal) role of telmisartan in reducing inflammation (by means of IL-18 and ESR), and its beneficial effects on the endothelium of the vessel wall (by means of endothelin-1 and cystatin C). Mixed-models analysis of covariance were used adjusting for changes in blood pressure and total cholesterol as a function of time in the study.
A two-tailed P-value ≤0.05 was considered significant. Analyses were carried out with the SAS 9.2 statistical package (SAS Institute, Inc., Cary, NC, USA).
Results
After matching inclusion and exclusion criteria, 18 Caucasian male HIV-positive patients were enrolled in the study. The main characteristics of patients at baseline are summarized in Table 1 . All patients had a stable HIV RNA<40 copies/ml and constant values of CD4 + T-cell counts throughout the study (T0 517 ±219 cells/ µl; T3 517 ±184 cells/µl; T6 503 ±171 cells/µl). Indices of liver and kidney function did not show any substantial changes.
With regards to the antihypertensive effect of telmisartan, statistically reduced levels of blood pressure were already observed at 1 month of treatment (systolic blood pressure [SBP] at T0 151 ±7 mmHg versus T1 138 ±5 mmHg, P<0.001; diastolic blood pressure [DBP] at T0 97 ±7 mmHg versus T1 87 ±6 mmHg, P<0.001). Such reductions were confirmed at T3 and T6, indicating good blood pressure control (P<0.001 versus baseline; Figure 1 ). These improvements were independent of MDRD-GFR and microalbuminuria (JV et al., data not shown).
Metabolic parameters showed an impairment of lipid parameters at baseline, which were improved throughout the study period. In particular, total cholesterol (T0 230 ±37 mg/dl versus T6 208 ±39 mg/dl; P<0.001), LDL cholesterol (T0 136 ±33 mg/dl versus T6 121 ±34 mg/dl; P<0.001) and triglycerides (T0 280 ±106 mg/dl versus T6 218 ±70 mg/dl; P<0.001) were decreased, whereas HDL cholesterol (T0 40 ±10 mg/dl versus T6 43 ±9 mg/dl; P<0.001) was increased. With regards to carbohydrate metabolism, although fasting glucose levels were not significantly altered throughout the study, a statistically significant decrease of HOMA-IR levels (T0 3.87 ±2.64 versus T6 3.23 ±1.93; P<0.01) was observed. All these changes in metabolic parameters were already statistically significant at T3 and were further improved at T6 (Table 2) . The Framingham cardiovascular risk score was statistically reduced after 6 months of treatment (16 ±8 versus 14 ±7 predicted cardiovascular events at 10 years; P=0.01). This finding was also confirmed by statistically significant decreased levels of indices of renal dysfunction, including cystatin C and microalbuminuria, whereas MDRD estimates of the glomerular filtration rate were stable.
Most patients had some improvement in the parameters studied; all parameters showed the same trend in most (>70%) patients.
Multivariate analysis showed that the reduction in cystatin C serum level was independent of SBP, DBP and total cholesterol (Figure 2) .
Telmisartan also exerted an anti-inflammatory effect: there was a statistically significant reduction of ESR and IL-18. A significant reduction of endothelin-1 was also observed. Multivariate analysis showed that reductions in ESR, IL-18 and endothelin-1 serum levels were affected independently of SBP, DBP and total cholesterol. Bonferroni-adjusted P-value for multiple comparisons. T0, baseline; T1, T3 and T6, 1 month, 3 months and 6 months after treatment, respectively. There were no adverse events, including gastrointestinal disturbances, or drop-outs during the study treatment and study compliance was complete.
Discussion
The main findings of this study are that a 6-month course of telmisartan (80 mg daily) in HIV-infected cART-treated patients with hypertension, besides resulting in effective blood pressure normalization, showed a reduction of patients' cardiovascular risk profile, with an improvement in insulin sensitivity, lipid profile and the overall Framingham risk score. Furthermore, telmisartan showed anti-inflammatory properties as well as reno-and endothelium-protective effects.
Hypertension is highly prevalent in HIV-infected patients, occurring 20 years earlier than in the general population [27] . Therefore, the choice of an effective antihypertensive therapy in HIV-infected patients is important and must be made carefully [28] . Antihypertensive drugs that interfere with the renin-angiotensin system, such as ACE-I and ARBs, might be ideal [9, 10] . The ONgoing Telmisartan Alone and in combination with Ramipril Global End-point Trial (ONTARGET) has shown that telmisartan is non-inferior to the ACE-I ramipril in patients with vascular diseases or high-risk diabetes [29] . A meta-analysis of randomized controlled trials indicated that telmisartan provides superior blood pressure control compared with ACE-I; moreover, telmisartan has fewer drug-related adverse events and better tolerability in hypertensive patients in general [30] . In the present study, a dosage of 80 mg telmisartan administered daily was used, as this dosage has been commonly utilized in the main antihypertensive trials with this drug [29] . Telmisartan was quickly efficacious and reduced both SBP and DBP significantly after only 1 month of therapy. A further improvement of SBP and DBP was observed throughout the study: there was a decrease in the mean values for SBP (reduced by 20 mmHg) and for DBP (reduced by 14 mmHg) at 6 months. These findings also seem to confirm the antihypertensive efficacy of telmisartan in HIV-infected patients treated with cART. Furthermore, the long terminal half-life of the drug (~24 h) [31] prompts a once-daily dosing regimen, which is a distinct advantage in HIV-infected cART-treated patients already taking several pills per day.
Several recent studies have revealed that telmisartan improves insulin sensitivity and lipid parameters in noninfected patients with hypertension or early-stage diabetes mellitus [18, 19, 21, 32] . As dyslipidaemia and insulin resistance have been frequently observed in the course of HIV infection and cART [33] , possible effects of telmisartan on metabolic parameters were postulated. In the present study in HIV-positive patients, telmisartan showed a very favourable activity on the lipid profile. Specifically, after 6 months of therapy we observed a reduction from baseline in triglycerides by 22.5%, in total cholesterol by 10% and in LDL cholesterol by 11%, whereas HDL cholesterol increased by 7.5%. Telmisartan also showed beneficial effects on glucose metabolism. Although fasting glucose levels were not significantly altered throughout the study, a rapid and progressive decrease of insulin resistance levels was observed and was confirmed at 6 months: there was a reduction of 16.5% from baseline. This finding is in keeping with previous data in a non-infected population with the metabolic syndrome [18] . The favourable effects of telmisartan on triglyceride levels and glucose metabolism might be explained by effective activation of PPAR-γ, but the mechanisms underlying the reduction in total cholesterol and LDL cholesterol are not well-understood [34] .
The observed metabolic effects were associated with a significant reduction in the calculated cardiovascular risk, as assessed by the Framingham risk score, which was reduced after 6 months of treatment. A decreased overall cardiovascular risk was also confirmed by the observed reduction of cystatin C, a novel marker of inflammation, atherosclerotic disease and cardiovascular risk, as well as renal complications, in the general population [35] [36] [37] . Data about cystatin C in HIV-infected patients are limited [38, 39] . In the present study, no patients had renal impairment and levels of cystatin C decreased significantly despite stable values of MDRD-GFR. As cystatin C is likely to be an inflammatory marker, this reduction might contribute to the overall decreased cardiovascular risk related to the use of telmisartan.
The use of telmisartan was associated with improved microalbuminuria in our study group, despite not causing significant changes in the glomerular filtration rate. Proteinuria is a feature of hypertensive renal damage. Microalbuminuria has been found to be an independent risk factor for CVD and mortality both in the general population and in HIV-positive patients [40, 41] . As previously shown [42, 43] , an anti-inflammatory effect of telmisartan was also observed in the present study, documented by significant reductions of the ESR and IL-18. IL-18 is a proinflammatory cytokine with pro-atherogenic properties, which might independently contribute to cardiovascular risk both in HIV-negative and in HIV-positive patients [33] .
Another interesting finding of this study is the significant reduction of endothelin-1 levels observed with the use of telmisartan. Endothelin-1 is a potent vasoconstrictor, proinflammatory and mitogenic peptide produced by endothelial and inflammatory cell types [44] . Its increased production and biological activity are important features of endothelial dysfunction, an early event in the development of atherosclerosis [45, 46] . PPAR-γ ligands have been demonstrated to inhibit cytokine-mediated endothelial cell proliferation and to suppress endothelin-1 secretion [47] [48] [49] . In the present study, we observed reduced endothelin-1 serum levels in HIV-infected patients with hypertension treated with telmisartan. The anti-inflammatory and endothelial protective effects of telmisartan might be unrelated to the effects on blood pressure, as pointed out from the multivariate analysis performed in this study.
Finally, telmisartan seems to have no direct effect on HIV replication and immunological parameters. In particular, telmisartan does not seem to interfere with cART, although further studies in this context are warranted.
A recent meta-analysis of randomized trials suggests a modestly increased risk of new cancer diagnosis associated with the use of ARBs; however, at present it is not possible to draw firm conclusions about the exact cancer risk associated with any such drug, as data are limited [50] .
We acknowledge several limitations in our study. A main limitation is the purely observational nature of our study with the lack of one or more parallel control arms. Future studies should include structurally unrelated ARBs without PPARγ-activating properties. Another limitation is the relatively small number of patients studied, resulting from our strict selection criteria. The Caucasian race of patients is another limitation, as it limits generalization of the results to other ethnic groups. Furthermore, the use of a single urine examination to measure microalbuminuria was not ideal, as a valid assessment of its values requires more than one measure. Finally, because this study did not include patients with renal disease, whether the results can be generalized to such patients remains unknown. All such issues might warrant further studies.
To our knowledge, this is the first study reporting the effects of telmisartan in patients with HIV infection and hypertension. The main findings of the present study are that treatment with telmisartan is safe, welltolerated and effective for the control of hypertension in HIV-positive individuals. Furthermore, improved insulin resistance and parameters of lipid metabolism, as well as an overall decrease in estimated cardiovascular risk, were observed. Finally, the use of telmisartan was associated with reno-protective, anti-inflammatory and endothelial protective properties.
If further studies confirm these findings, the cardiometabolic sartan telmisartan might well be the antihypertensive drug of choice in hypertensive HIVpositive patients.
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